Designing Paclitaxel Drug Delivery Systems Aimed at Improved  Patient Outcomes: Current Status and Challenges

<table>Drug concentration versus time curves of [<sup>3</sup>H]paclitaxel in lipid emulsion (●), [<sup>3</sup>H]paclitaxel in Cremophor EL : ethanol 1 : 1 (v/v) (▿), and [<sup>3</sup>H]paclitaxel oleate in lipid emulsion (▪) following single i.v. bolus. Values are mean ± S.D., <svg height="10.9125" id="M3" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 35.099998 10.9125" width="35.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.9125)">
<g transform="translate(72,-63.27)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">3</tspan>
</text>
</g>
</g>
</svg>. *<i>P </i>&lt; 0.05 versus paclitaxel in Cremophor EL/ethanol (reproduced with permission from Lundberg et al., [<a href="/journals/isrn/2012/623139/#B64">64</a>]).</table>

International Scholarly Research Notices

fig15

Figure 15

Figure 15: Designing Paclitaxel Drug Delivery Systems Aimed at Improved  Patient Outcomes: Current Status and Challenges 